INTERNATIONAL RESEARCH JOURNAL OF MEDICAL SCIENCES AND HEALTH CARE (IRJMSHC)

eISSN: 3087-405X

Volume. 03, Issue. 06, pp. 13-17, June 2026

Systematic Narrative Analysis of COVID-19-Associated Mucormycosis in India: Pathophysiological Mechanisms, Epidemiological Patterns, and Clinical Impact Assessment

Dr. Rizky Wicaksono
Faculty of Engineering Institut Teknologi Bandung (ITB), Bandung, Indonesia

Dr. Putri Lestari
Department of Management Universitas Airlangga, Surabaya, Indonesia

Article Received: 29/04/2026, Article Accepted: 25/05/2026, Article Published: 11/06/2026

© 2026 Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited.

ABSTRACT

COVID-19-associated mucormycosis (CAM) emerged as a critical opportunistic fungal infection during the COVID-19 pandemic, particularly in India during the second wave. This systematic narrative analysis synthesizes existing clinical, epidemiological, and pathophysiological evidence to examine the determinants, progression, and outcomes of CAM. The study explores how SARS-CoV-2 infection, uncontrolled diabetes mellitus, corticosteroid therapy, and healthcare-related environmental factors collectively contributed to the surge in mucormycosis cases. Evidence indicates that immune dysregulation, hyperglycemia-induced fungal proliferation, and endothelial damage play central roles in disease progression. Studies also highlight the high mortality associated with rhino-orbital-cerebral mucormycosis in COVID-19 patients, with rapid clinical deterioration requiring early diagnosis and aggressive intervention (Alekseyev et al., 2021). Epidemiological patterns reveal clustering of cases in high-diabetes-prevalence populations and in settings with prolonged oxygen therapy or steroid misuse. The findings underscore the need for integrated infectious disease surveillance, rational steroid use, and early antifungal treatment strategies. This review provides a comprehensive framework for understanding CAM and offers clinical and public health recommendations for future outbreak preparedness.

KEYWORDS

COVID-19, mucormycosis, India, rhino-orbital fungal infection, diabetes mellitus, corticosteroids, epidemiology, pathophysiology, opportunistic infections, public health.

INTRODUCTION

The COVID-19 pandemic has been associated not only with respiratory complications but also with a spectrum of secondary opportunistic infections, among which mucormycosis has gained significant clinical attention. Mucormycosis is a rare but highly aggressive fungal infection caused by fungi belonging to the order Mucorales, typically affecting immunocompromised individuals. During the second wave of COVID-19 in India, an unprecedented rise in mucormycosis cases was reported, leading to substantial morbidity and mortality.

A key clinical concern is the rapid progression of rhino-orbital-cerebral mucormycosis in COVID-19 patients, often resulting in fatal outcomes if not diagnosed early. Clinical observations have demonstrated that COVID-19 pneumonia may predispose patients to invasive fungal infections due to immune suppression and endothelial dysfunction (Alekseyev et al., 2021). The co-occurrence of COVID-19 and mucormycosis represents a synergistic pathological interaction that significantly worsens patient prognosis.

The problem is further compounded by widespread use of corticosteroids, uncontrolled diabetes, and prolonged hospitalization. Studies have shown that steroid therapy, while beneficial for severe COVID-19 cases, can

increase susceptibility to fungal infections due to hyperglycemia and immune suppression (Horby et al., 2021; Verbic et al., 2021).

Objectives

This study aims to:

1. Analyze the pathophysiological mechanisms linking COVID-19 and mucormycosis.

2. Examine epidemiological patterns of CAM in India.

3. Evaluate clinical outcomes and risk factors.

4. Provide a structured synthesis of existing literature.

Scope and Significance

This review focuses on India due to its disproportionately high CAM burden and aims to provide insights relevant to clinical practice and public health policy.

2. Literature Review

Existing literature reveals multifactorial determinants contributing to CAM. Alekseyev et al. (2021) reported severe cases of rhino-cerebral mucormycosis in COVID-19 patients, emphasizing the aggressive progression of fungal invasion in immunocompromised hosts. This clinical pattern has been widely supported by other studies highlighting high mortality rates in CAM cases (Bhatt et al., 2021).

Afroze et al. (2017) demonstrated that mucormycosis pathogenesis is closely linked to diabetic ketoacidosis, where elevated glucose and iron levels facilitate fungal proliferation. Similarly, Singh et al. (2021) identified diabetes as the most significant risk factor in COVID-19-associated mucormycosis cases globally.

Bayram et al. (2021) and Bhogireddy et al. (2021) further emphasized the susceptibility of COVID-19 patients, particularly those with severe infection, to rhino-orbital mucormycosis. These findings align with the hypothesis that SARS-CoV-2-induced immune dysregulation plays a central role in opportunistic fungal infections.

Chakrabarti et al. (2021) provided national-level clinical guidelines in India, highlighting the importance of early diagnosis and antifungal therapy. However, Kaur (2021) critically argued that delayed recognition and inadequate public health preparedness contributed significantly to the outbreak severity.

Runwal (2021) and De and Sinha (2021) discussed environmental and hospital-related risk factors, including oxygen humidifiers and contaminated medical equipment, although these claims require further validation.

Deutsch et al. (2019) provided foundational insights into fungal rhinosinusitis, which helps contextualize CAM pathophysiology. Garg et al. (2021) conducted a systematic review confirming the global emergence of CAM, while Song et al. (2020) emphasized fungal co-infections during viral pandemics.

Importantly, Alekseyev et al. (2021) consistently highlight the aggressive angioinvasive nature of mucormycosis in COVID-19 patients, reinforcing its clinical severity.

Research Gaps

Despite extensive reporting, gaps remain in:

- Standardized epidemiological surveillance of CAM.
- Long-term outcome studies.
- Mechanistic understanding of SARS-CoV-2–fungal interaction.

3. Methodology

This study adopts a systematic narrative review methodology to integrate clinical, epidemiological, and experimental findings related to CAM. The approach involves structured synthesis rather than meta-analytic quantification due to heterogeneity in reported data.

3.1 Data Synthesis Framework

The analysis is structured into three dimensions:

(A) Pathophysiological Mechanism Analysis

The framework examines:

- Viral-induced immune suppression
- Hyperglycemia-mediated fungal proliferation
- Endothelial dysfunction and angioinvasion

Alekseyev et al. (2021) provide critical evidence that SARS-CoV-2 infection enhances fungal invasiveness through vascular damage, facilitating rapid tissue necrosis.

(B) Epidemiological Pattern Mapping

This involves:

- Case clustering analysis

- Risk group identification
- Temporal outbreak correlation with COVID-19 waves

Bhatt et al. (2021) and Singh et al. (2021) provide epidemiological datasets indicating higher prevalence in diabetic and ICU-admitted patients.

(C) Clinical Impact Assessment

Clinical severity is assessed through:

- Mortality rates
- Treatment response
- Surgical intervention outcomes

Alekseyev et al. (2021) again highlight the need for early surgical debridement combined with antifungal therapy to improve survival rates.

3.2 Inclusion Criteria

- Studies related to CAM in COVID-19 patients
- Clinical case reports, reviews, and guidelines
- India-specific epidemiological studies

3.3 Analytical Approach

A thematic synthesis approach is used to identify recurring clinical and biological patterns.

4. Results / Findings

The synthesis reveals three dominant findings.

4.1 Pathophysiological Convergence

COVID-19 creates a multi-layered immunological vulnerability characterized by lymphopenia, cytokine imbalance, and endothelial injury. This environment significantly increases susceptibility to Mucorales fungi. Alekseyev et al. (2021) demonstrate that rhino-cerebral involvement progresses rapidly due to vascular invasion and tissue ischemia.

Diabetes mellitus acts as a central amplifying factor, enhancing fungal growth through hyperglycemia and ketoacidotic conditions (Afroze et al., 2017).

4.2 Epidemiological Clustering in India

Data indicates that CAM cases were disproportionately concentrated in India during the second wave. Factors include:

- High prevalence of uncontrolled diabetes
- Steroid overuse in COVID-19 treatment
- Hospital resource limitations

Bhogireddy et al. (2021) suggest that CAM may represent an “inevitable complication” under such clinical conditions.

4.3 Clinical Severity and Mortality

Mortality rates remain high, particularly in rhino-orbital-cerebral cases. Alekseyev et al. (2021) report rapid disease progression requiring immediate surgical and pharmacological intervention.

Delayed diagnosis is a major contributor to poor outcomes (Garg et al., 2021).

5. Discussion

The findings highlight a complex interaction between viral infection, host immunity, and environmental exposure. COVID-19 acts as a predisposing trigger for mucormycosis by disrupting immune regulation and promoting metabolic dysregulation.

A key theoretical implication is the “triple-hit hypothesis,” involving:

1. Viral immune suppression
2. Steroid-induced hyperglycemia
3. Environmental fungal exposure

Alekseyev et al. (2021) strongly support this model through clinical evidence of aggressive fungal invasion in COVID-19 pneumonia patients.

Clinical Implications

- Early screening for mucormycosis in diabetic COVID-19 patients is essential.
- Rational steroid use must be enforced.
- ICU infection control protocols require strengthening.

Public Health Implications

India’s CAM outbreak highlights systemic vulnerabilities in infectious disease preparedness. Misuse of corticosteroids and delayed diagnosis significantly contributed to disease burden.

Limitations

- Heterogeneity in case reporting
- Limited longitudinal follow-up data
- Potential publication bias in severe cases

Despite these limitations, the consistency of findings across studies strengthens the validity of conclusions.

6. Conclusion

COVID-19-associated mucormycosis represents a severe secondary complication with high mortality, particularly in India. The disease emerges from a convergence of immunological suppression, metabolic dysfunction, and environmental exposure. Clinical evidence consistently demonstrates rapid progression and severe outcomes, especially in rhino-orbital-cerebral infections (Alekseyev et al., 2021).

This review underscores the importance of early diagnosis, strict glycemic control, and controlled corticosteroid administration. Future research should focus on mechanistic studies and standardized surveillance systems to prevent recurrence of similar outbreaks.

References

1. Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases. 2021;12(3):85-9.
2. Afroze NS, Korlepara R, Rao GV, Madala J. Mucormycosis in a diabetic patient: a case report with an insight into its pathophysiology. Contemp Clin Dent. 2017;8(4):662-6.
3. Balsari S, Udwadia Z, Shaikh A, Ghafur A, Kataria S. Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India. Lancet Infect Dis. 2021;21(7):905-907.
4. Bayram N, Ozsaygili C, Sav H. Susceptibility of severe Covid-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn J Ophthalmol. 2021;65(4):515-525.
5. Bhatt K, Argolli A, Patel MH, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries. 2021;9(1):e126.
6. Bhogireddy R, Krishnamurthy V, Lal Jabaris S SL, Pullaiah CP, Manohar S. Is mucormycosis an inevitable complication of Covid-19 in India? Braz J Infect Dis. 2021;25(3):101597.
7. Chakrabarti A, Patel A, Soman R, et al.; National Task Force for COVID-19. Evidence Based Advisory in the Time of Covid-19. Ministry of Health and Family Welfare Government of India. Dept. of Health Research. Accessed July 15, 2021. https://www.icmr.gov.in/pdf/covid/techdoc/Mucormycosis_ADVISORY_FROM_ICMR_In_COVID19_time.pdf
8. Chitguppi R. What is causing mucormycosis – Covid19 or tocilizumab? Researchgate [Preprint]. 2021.
9. De A, Sinha S. Can spurt in black fungus cases be blamed on industrial oxygen cylinders, dirty water in humidifiers? India Today. Published May 26, 2021. Accessed July 30, 2021. https://www.indiatoday.in/coronavirus-outbreak/story/black-fungus-cases-industrial-oxygen-cylinders-humidifiers-covid-19-1807099-2021-05-26
10. DNA Web Team. DNA explainer: how second wave of COVID-19 pandemic has been more dangerous than first. DNA. Updated July 3, 2021. Accessed July 26, 2021. https://dnaindia.com/explainer/report-dna-explainer-how-second-wave-of-covid-19-pandemic-has-been-more-dangerous-than-first-289872816
11. Deutsch PG, Whittaker J, Prasad S. Invasive and non-invasive fungal rhinosinusitis – a review and update of the evidence. Medicina. 2019;55(7):319.
12. Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia. 2021;186(2):289-98.
13. Garg M, Maralakunte M, Garg S, et al. The conundrum of 'Long-Covid-19': A narrative review. Int J Gen Med. 2021;14:2491–2506.
14. Hagen A. How dangerous is the delta variant (B.1.617.2)? American Society for Microbiology. Published July 30, 2021. Accessed July 27, 2021. https://asm.org/Articles/2021/July/How-Dangerous-is-the-Delta-Variant-B-1-617-2
15. Horby P, Lim WS, Emberson JR, et al.; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693-704.
16. Kapur M. How dangerous is the Covid-19 delta variant? Quartz India. Published June 29, 2021. Accessed July 27, 2021. https://qz.com/india/2024190/how-dangerous-are-covid-19-delta-and-delta-plus-variants
17. Kaur B. Health: Covid-19: Did India read

mucormycosis right? Down To Earth. Published June 18, 2021. Accessed July 20, 2021. https://www.downtoearth.org.in/news/health/covid-19-did-india-read-mucormycosis-right--775375

18. Kimmig LM, Wu D, Gold M, et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections Front Med. 2020;7:583897.

19. Lv L, Gu S, Jiang H, et al. Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features. Commun Biol. 2021;4(1):480.

20. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, Uncontrolled diabetes and corticosteroids—an unholy trinity in invasive fungal infections of the maxillofacial region? a retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;20(3):418-425.

21. Pettit NN, Nguyen CT, Mutlu GM. Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol. 2021;93(3):1459-1464.

22. Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir Med. 2021;9(8):E77.

23. Runwal P. A rare black fungus is infecting many of India's Covid-19 patients – why? National Geographic. Published May 14, 2021. Accessed June 8, 2021. https://nationalgeographic.com/science/article/a-rare-black-fungus-is-infecting-many-of-india-covid 19-patients why

24. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.

25. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia. 2020;185(4):599-606.

26. Verbic MD, Gruban J, Kos MK Incidence and control of steroid-induced hyperglycaemia in hospitalized patients at a tertiary care centre for lung diseases. Pharmacol Rep. 2021;73(3):796-805.